Get the Stockscreener App
120.72
1.84%
2.18
After Hours:
120.72
Biontech Se Adr Stock (BNTX) Latest News
BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
Stocks Showing Improving Market Leadership: BioNTech ADR Earns 81 RS Rating - Investor's Business Daily
BioNTech ADR Earns Relative Strength Rating Upgrade - Investor's Business Daily
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
BioNTech Stock Got A IBD RS Rating Lift - MSN
BioNTech ADR Shows Improved Relative Strength; Still Shy Of Benchmark - Inkl
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
Analysts Turn Bullish on BioNTech Stock Amid Volatility - Schaeffers Research
10 Biggest Biotechnology Companies - Investopedia
The Best Biotech Stocks to Buy - Morningstar
BioNTech SE ADR (BNTX): An Important Analyst Insights - Stocks Register
BioNTech SE ADR falls Friday, underperforms market - MarketWatch
Powell Speaks The Truth - Benzinga
Goodwin, Conyers, A&O Shearman Act on $800M China Biotech Sale - Law.com International
BioNTech SE ADR rises Wednesday, outperforms market - MarketWatch
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition - Benzinga
BioNTech SE ADR falls Monday, underperforms market - MarketWatch
BioNTech SE ADR rises Friday, outperforms market - MarketWatch
BioNTech Earnings: Strong Covid Revenue, but Full-Year Expectations Unchanged - Morningstar
BioNTech SE Reports Strong Q3 2024 Results - TipRanks
This 6%-yielding U.S. pharma giant is a safe hold - The Globe and Mail
BioNTech SE ADR outperforms market despite losses on the day - MarketWatch
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings? - Nasdaq
BioNTech to Report Q3 Earnings: Is a Beat in the Cards? - MSN
BioNTech SE ADR rises Thursday, outperforms market - MarketWatch
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
BioNTech SE ADR rises Wednesday, still underperforms market - MarketWatch
A better buy-in window may exist right now for BioNTech SE ADR (BNTX) - SETE News
Insider’s View: Deciphering BioNTech SE ADR (BNTX)’s Financial Health Through Ratios - The Dwinnex
BioNTech SE ADR (BNTX)’s stock decline to 121.55 per share - US Post News
BioNTech SE ADR falls Monday, still outperforms market - MarketWatch
What is BioNTech SE ADR (BNTX) Stock Return on Shareholders’ Capital? - SETE News
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):